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Abstract: This is a review of the clinical trials investigating the efﬁ  cacy and safety of risperidone 
in the treatment of children with autistic spectrum disorders (ASD). The main clinical charac-
teristics are impairment in social skills, communication difﬁ  culties, repetitive movements and 
behaviors, including stereotypies. Pharmacotherapy is mainly directed at the so-called target 
symptoms, ie, behavioral disorders and the various kinds of repetitions associated with ASD. 
According to the available data, risperidone seems to be moderately efﬁ  cacious and safe for 
treating behavioral disorders. 4 double blind controlled trial. 3 reanalysis studies, and 12 open 
studies have documented the role of risperidone in children with ASD. Controlled studies have 
been thoroughly considered in this review.
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Introduction
Autism spectrum disorders (ASD) are characterized by impaired development of 
social interaction and reciprocity, communication difﬁ  culties affecting language and 
nonverbal skills, and repetitive patterns of movements and behaviors which include 
restricted interests and activities. Although they are not included in the diagnostic 
criteria, learning disabilities affect as much as two thirds of individuals with ASD 
(APA 1994).
They are deﬁ  ned as pervasive developmental disorders (PDDs) in DSM IV clas-
siﬁ  cation and include the following diagnostic categories: autistic disorder, Asperger 
disorder, Rett disorder, childhood disintegrative disorder, and pervasive developmental 
disorder not otherwise speciﬁ  ed (PDD-NOS) including the different forms of atypical 
autism not matching the diagnostic criteria for the other PDDs.
Autistic disorder (AD), or autism, is the most common PDD/ASD with a recently 
estimated prevalence of 13 per 10,000. The etiology of AD is still unknown, although 
genetic factors are probably involved, and in 5% to 10% of cases there is an identiﬁ  -
able associated known medical condition. The onset of autistic disorder has been set 
at before the age of 3 years, and other ASDs may have a later onset (APA 1994). The 
prevalence of Asperger’s disorder is approximately 3 per 10,000 and childhood dis-
integrative disorder is very rare, estimated at 0.2 per 10,000. Rett disorder prevalence 
is 1 per 15000. The prevalence of all PDDs in recent surveys is about 60 per 10,000 
(Fombonne 2005).
Behavioral disturbances are fairly common in these disorders and are very often 
challenging to treat. Tantrums, aggressive behavior, and overactivity/hyperactivity 
are frequent from the early phases and may last throughout adulthood, causing serious 
problems in adaptation. The severity and the development of the various symptoms Neuropsychiatric Disease and Treatment 2008:4(4) 724
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and their clinical features vary on an individual basis. 
When behavioral problems interfere with general well-
being, daily activities, and with the therapeutic program, 
pharmacological intervention should be considered (Aman 
2004). The so-called target symptoms are therefore tack-
led by pharmacotherapy with a symptom-based approach. 
Antipsychotics have been used to control aggression, 
self-injurious behavior and overactivity/hyperactivity in 
ASD. Typical antipsychotics have been found to be useful 
in limiting temper tantrums, hyperactivity, and repetitive 
movements, and they have also been reported to be effec-
tive in improving social interaction. Typical antipsychotics 
have been extensively used clinically in ASD, but they 
have not been extensively evaluated, with the exception 
of Campbell’s studies with haloperidol (Campbell et al 
1997). Unwanted extrapyramidal effects (UEE) have been 
a major drawback in the use of these agents and the advent 
of atypical antipsychotics has provided a safer option in 
the therapeutic approach to ASD. Furthermore, movement 
disorders are often difﬁ  cult to evaluate in this patient popu-
lation since unusual stereotipies and repetitive movements 
are part of the core disorder, thus it is often difﬁ  cult to 
distinguish between movement disorders that are intrinsic 
to ASD and those that are possibly related to treatment 
(Campbell et al 1999).
Atypical antipsychotics, such as risperidone, are being 
studied for the treatment of behavioral symptoms in ASD 
due to their increased safety and efﬁ  cacy compared to con-
ventional neuroleptics (Barnard et al 2002). Most data have 
been collected on the use of risperidone in children aged 5 
and older, but there is still a lack of research in preschool 
children (Chavez et al 2006; West and Waldrop 2006; Jesner 
et al 2007). This paper reviews the use of risperidone in 
children and adolescents with ASD, particularly regarding 
the treatment of associated behavioral disorders.
Method
A MEDLINE/Pubmed search was performed, ending in 
February 2007, on the use of risperidone in children with 
ASD. The key words used were: autism, pervasive develop-
mental disorders and risperidone. A total of 4 double-blind, 
placebo controlled trials were found and 2 additional studies 
were also found which were based on the reanalysis of the 
data. The results of these studies have been reviewed and 
summarized below (Table 1). Furthermore, 12 open label, 
several observational or retrospective trials and case reports 
have also been published. They are synthetically presented 
in Table 2.
Risperidone efﬁ  cacy and safety 
in children and adolescents with ASD
•  The RUPPAN study (McCracken et al 2002) [ages: 5–17 
yrs; risperidone dose: 1.8 mg/day; outcome measurement: 
ABC-I (and CGI-I); percentage of improvement 69%].
The ﬁ  rst RUPPAN (Research Units on Pediatric Psy-
chopharmacology Autism Network) trial was conducted in 
a group of children with a diagnosis of autistic disorder as 
deﬁ  ned in the DSM-IV. Additional inclusion criteria were 
behavioral disturbances: aggression, hyperactivity, self-
injury and tantrums in varying combinations. The irritabil-
ity subscale of the aberrant behavior checklist (ABC) was 
used to rate these symptoms and a score of at least 18 was 
required for inclusion in the study (Aman et al 1985). The 
assessment was carried out twice to conﬁ  rm that the entry 
criteria had been met. The two groups were made up of 49 
and 52 children, with a total of 82 boys and 19 girls.
The Clinical Global Impression – Severity (CGI-S) scale 
was used to evaluate the children’s symptoms at baseline, 
and the Clinical Global Impression – Improvement scale 
(CGI-I) was used to evaluate changes during the trial. Eigh-
teen children were found to have moderate severity on the 
CGI-S, 55 were rated as having marked severity, 24 had 
severe impairment, and 1 child had extreme impairment. No 
statistically signiﬁ  cant differences were found in any of the 
baseline scores between the two treatment groups.
The dosage of risperidone was established on the basis 
of the weight of patients. The starting dose was 0.25 mg/
day if the child’s weight was less than 20 kg, and 0.5 mg if 
the child’s weight was between 20 and 45 kg, and in this case 
the dose was increased to 0.5 mg twice daily on day 4. The 
titration scheme was the following: for children weighing 
less than 45 kg, the dose was increased by 0.5 mg accord-
ing to the clinical response. For children weighing 45 kg 
or more, dose increase was accelerated without specifying 
the actual doses. Maximum dosage was 2.5 mg for children 
weighing less than 45 kg, and 3.5 mg for children weighing 
45 kg or more.
Primary outcome measures were the Irritability subscale 
of the ABC, considering a score of 18 as the population aver-
age, and the rating on the CGI-I. A decrease in the irritability 
score was detected in the risperidone group (p < 0.001). 
Seventy-ﬁ  ve percent of children on risperidone were rated 
as much improved or very much improved on the CGI-I 
versus 11.5% of children in the placebo group (p < 0.001). 
Participants had to have at least a 25% reduction in the irrita-
bility subscale and a rating of much improved or very much Neuropsychiatric Disease and Treatment 2008:4(4) 725
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Table 1 Clinical trials of risperidone for children with ASD/PDD
Design Pts.(N) Age (y) Mean dose 
(mg/day)
Results
RUPPAN (2002) 8 wk, DB, PC 101 5–17 1.8 Improvement on ABC in irritability, 
stereotypy, hyperactivity; improved 
CGI-I
Shea (2004) Reanalysis 8 wk, DB, PC 79 5–12 1.48 Improvement in irritability, 
stereotypy hyperactivity, insecurity/
anxiety; oversensitivity in ABC and 
N-CBRF, also in language and social 
withdrawal
RUPPAN (2005) Reanalysis 4 mo, OL, 
followed for 8 wk, DB, 
PC discontinuation 
phase
63 5–17 2.08 Improvement in ABC in irritability; 
continued improvement on CGI-I; 
during discontinuation phase, 
placebo-treated pts. relapsed more 
often and sooner
McDougle (2005) Reanalysis of Database 
from RUPPAN (8 wk, 
DB, PC)
101 5–17 1.8 No improvement in social and 
communication skills; improve-
ment in sensory motor behaviors, 
affective reactions; decreased 
stereotypy on CY-BOCS
Luby (2006) 6 mo, DB, PC 24 2.5–6 0.5–1.5 Improvement in core symptoms 
(CARS)
Pandina (2006) Reanalysis of Database 
from RUPPAN (8 wk, 
DB, PC)
55 5–12 1.48 Hyperactivity, aggression and 
irritability
Nagaray (2006) 6 mo, DB, PC 40 2–9 1* CARS, C-GAS
Abbreviations: ABC, Aberrant Behavior Checklist; ASD/PDD, autism spectrum disorder/pervasive developmental disorders; CGI-I, Clinical Global Impression-Improvement; 
CY-BOCS, Children’s Yale-Brown Obsessive Compulsive Scale; DB, Double-blind; N-CBRF, Nisonger-Child Behavior Rating Form; OL, open-label; PC, placebo-controlled; 
R-FRLRS, Ritvo-Freeman Real Life Rating Scale; RUPPAN, Research Units on Pediatrics Psychopharmacology Autism Network; 1 mg, *Fixed Dose.
Table 2 Open-label studies of risperidone in children with autism
Pts. (n) Age (ys) Mean dose 
(mg/day)
Results
Fisman and Steele 
(1996)
14 9–17 1.1 13 pts. Improved on CGAS, agitation, anxiety, 
disruptive behaviors, social awareness
McDougle (1997) 18 5–18 1.8 12 pts. improved on CGI-I, repetitive behavior, 
aggression, impulsivity
Findling (1997) 6 5–9 1.1 Effective in all 6 pts. in problematic behaviors; 
improvement on CPRS and CGI-I
Nicolson (1998) 10 4–10 1.3 8 of 10 showed improvement on CPRS and CGI-I
Zuddas (2000) 11 7–17 2.7 Improvement in behavioral symptoms in 10 pts.; 
results maintained for 12 months
Masi (2001) 24 3.6–6.6 0.5 8 pts. showed improvement on CPRS and CGI-I
Diler (2002) 20 3–7 1.5 13 pts. had a positive response on CGI-I
Malone (2002) 22 3–16 1.8 Signiﬁ  cant improvements in CPRS and CGI-I for 
10 pts.
Gagliano (2004) 20 3–10 1.3 8 showed improvement on CPRS and CGI-I
Troost (2005) 36 5–17 1.8 24 pts. where considered responders. In the 
double-blind discontinuation phase, 8 out of 12 on 
placebo relapsed vs 3 out of 12 on risperidone.
Raush (2005) 13 6–12 1.0 9 pts. had reduction in SAN
Canitano (2006) 11 6–10 0.6 Reduction in frequency of self-injurious behaviors 
in 9 pts. YAPA-SIB
Abbreviations: C-GAS, Children’s Global Assessment Scale; CGI-I, Clinical Global Impression-Improvement; CPRS, Children’s Rating Scale; PDD, pervasive developmental 
disorders; SANS, Scale for Assessment of Negative Symptoms; YAPA-SIB, Yale-Paris Self-Injurious Behavior Scale.Neuropsychiatric Disease and Treatment 2008:4(4) 726
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improved in the trial in order to be considered as responders. 
Accordingly, 34 (69%) of the 49 children were responders 
in the risperidone group and 6 (12%) of the 52 in placebo 
group. Hyperactivity and stereotypy subscales of ABC as 
secondary measures also showed an improvement in the 
risperidone group.
The most frequently observed side effects were weight 
gain, increased appetite, fatigue, drowsiness, drooling, diz-
ziness, constipation, tremor, and tachycardia. The average 
weight gain was 2.7 ± 2.9 kg. Improvement was observed 
in the majority of children by week 4. Three children in the 
risperidone group withdrew due to a lack of effectiveness 
compared to 18 withdrawals in the placebo group.
A 4-month open-label extension of the trial was accepted 
by 23 (68%) of the children labeled as positive responders 
and all of them maintained the positive trend during that 
period.
•  The McDougle study (McDougle et al 2005) [reanalysis 
to assess stereotypy/repetitive behaviors, outcome mea-
surement: CY-BOCS; effect size d = 0.55; 69% percent 
improvement. Responders were subsequently enrolled in 
the open label and discontinuation phase].
The RUPPAN database was then used by McDougle 
and colleagues (2005) to further develop the analysis of 
risperidone efﬁ  cacy. The aim of this study was to verify 
risperidone efﬁ  cacy on the core symptoms of autism (social 
impairment, communication deﬁ  cits, stereotypies). The 
variation of repetitive movements and behaviors, including 
stereotypies, is particularly important for the purpose of 
this review and is presented in detail. A modiﬁ  ed version 
of the Children Yale-Brown obsessive compulsive scales 
(CY-BOCS) was used to assess these aspects because of 
the difﬁ  culties in language and expression of children with 
autism. This is a 10 item clinician rated scale normally used 
for obsessive-compulsive disorder, and the CY-BOCS score 
in this study was 20 points. At week 8, a signiﬁ  cant reduc-
tion of repetitive behaviors was observed in the risperidone 
group (score decrease from 15.51 ± 2.73 to 11.65 ± 4.2, and 
in the placebo group from 15.18 ± 3.88 to 14.21 ± 4.821, 
p = 0.005).
Patients who had a positive response to the 8 week trial 
were given the option of entering the 4-month open-label 
phase of the study. Furthermore, nonresponders to placebo 
were given the option of participating in an 8-week open-
label treatment with risperidone. If they had a positive 
response, they were given a further option of entering the 
4-month open-label phase.
At the end of the 4 months, responders entered the 
discontinuation phase. They were randomly assigned to 
continue risperidone treatment or to be tapered off to placebo. 
A total of 63 patients entered the 4-month open-label phase. 
The two primary outcome measurements were the irritability 
subscale on ABC and CGI-I. A total of 51 (81%) subjects 
completed the open-label phase and all the children contin-
ued to show a positive response to the treatment. Twelve 
children withdrew from this phase, 5 because of loss of 
efﬁ  cacy. The most common adverse events were increased 
appetite and sedation. Of the 51 patients who completed the 
open-label phase, 38 entered the discontinuation phase. Ten 
out of 16 patients in the placebo group and 2 out of 16 in the 
risperidone group had a relapse. The median time periods to 
relapse were 34 and 57 days in the placebo and risperidone 
groups, respectively.
•  The Shea study (Shea et al 2004) [ages: 5–12 yrs, ris-
peridone dose; 0.06 mg; outcome measurement: ABC-I 
score; percentage of improvement: 64% of children].
Shea and colleagues (2004) conducted an 8-week double 
blind, placebo-controlled study of risperidone for the treat-
ment of disruptive behavioral symptoms in children and 
adolescents with ASD (Schopler et al 1980). The participants 
had to meet DSM-IV criteria for autism or other PDD and had 
to have a score of at least 30 on the Childhood Autism Rating 
Scale (CARS) with or without mental retardation (RUP-
PAN 2005) The ﬁ  nal mean dose was 0.05 mg/kg/day with 
a maximum mean dose of 0.06 mg/kg/day. Forty-one of the 
79 children were randomized to receive risperidone and 39 
received placebo, and at the end of the trial, the participants 
showed 64% and 31% improvement in the ABC irritability 
subscale, respectively. Notably, a signiﬁ  cant decrease in 
the ABC subscales exploring the core symptoms of ASD, 
such as inappropriate speech and lethargy/social withdrawal, 
was also observed. Furthermore, a signiﬁ  cant decrease was 
observed in hyperacitvity/compliance ABC subscales and in 
the Nisonger Behavior Rating Form (NCBRF) subscales of 
conduct, insecure/anxious, hyperactive and oversensitivity 
(Aman et al 1996). With the use of CGI-I, 21 (51%) patients 
on risperidone were rated as much improved or very much 
improved compared to only 7 (18%) patients in the placebo 
group (p < 0.005).
Somnolence was the most common side effect in children 
on risperidone. The mean weight gain in the risperidone 
group was 2.7 kg, while in the placebo group it was 1.0 kg. 
Tachycardia, upper respiratory infections, and rhinitis 
occurred more frequently in the risperidone group. Unwanted Neuropsychiatric Disease and Treatment 2008:4(4) 727
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extrapyramidal side effects were reported in 11 patients on 
risperidone and in 5 on placebo, tremor, and hypokinesia 
were the most common.
•  The Pandina reanalysis study (Pandina et al 2007) [out-
come measurement: ABC-I, ABC-I plus CGI-I; effect 
size: 0.7; composite score responders: 58.3%].
A secondary analysis of the data of Shea’s study was 
conducted by Pandina and colleagues (2007) to further 
evaluate the efﬁ  cacy and safety of risperidone treatment 
(Nicolson et al 1998). The same behavior and clinical 
assessment measurements used in the RUPP study were 
carried out and evaluation of the current most disturbing 
symptoms was also included. Primary efﬁ  cacy measurement 
was the irritability subscale of the ABC, and secondary efﬁ  -
cacy measurements were the same as those used in Shea’s 
study (ABC subscales scores and N-CBRF subscale scores, 
The visual analog scale for the most troublesome symptom 
(VAS-MS) and CGI-I). As a post-hoc analysis, treatment 
response was determined by identifying composite respond-
ers with an improvement of 25% in the ABC-irritability 
subscale plus a CGI-I score of 2 (eg, much or very much 
improved) for a composite score. A total of 80 ASD patients 
were enrolled in Shea’s original study, and of these 55 were 
children with a diagnosis of autistic disorder according to 
the DSM-IV. A CARS score of 30 was also required for 
inclusion in the study.
Twenty-ﬁ  ve (92.6%) of subjects receiving risperidone 
and 24 (85.7%) of the placebo group completed 8 weeks of 
treatment. Subjects dropped out of the risperidone group due 
to insufﬁ  cient response (1) and extrapyramidal disorders (1). 
The changes in the VAS for the most troublesome symptom 
data were also favorable in the risperidone group. CGI-I 
and composite response (25% ABC irritability subscale 
and CGI-I much or very much improved) endpoint changes 
further conﬁ  rmed that children in the risperidone group 
had undergone a signiﬁ  cant improvement. There was also 
a consistent reduction in hyperactivity and aggression, the 
most troublesome symptoms mentioned by parents, in the 
risperidone group.
This secondary analysis showed that risperidone was 
superior to the placebo in controlling behavioral distur-
bances in more than half of the participants. Among the 
adverse events reported, weight gain was mild, perhaps 
due to the low doses of risperidone used, at a mean dose 
of 1.37 mg/day vs 1.8 mg/day in the RUPP trial. The small 
sample size and the brief duration of the study were the 
major limitations.
Risperidone safety and efﬁ  cacy 
in preschool children with ASD: 
age 2.5–6 years
Studies of the efﬁ  cacy of risperidone in the treatment of 
ASD among preschool children have been extremely limited 
and are mostly case reports or open-label trials. The largest 
available open-label study was conducted on preschoolers 
with ASD, aged 3.9–6.6 yrs, by Masi and colleagues (2003). 
The signiﬁ  cant ﬁ  nding was that core social impairment 
and verbal and nonverbal communication skills improved, 
which most previous studies had failed to demonstrate. To 
date, there have been two controlled studies of risperidone 
in children with ASD.
•  Luby's study (Luby et al 2006) [ages 2.5–6 yrs, risperi-
done dose 0.5–1.5 mg; CARS score; effect size 0.95].
This was the ﬁ  rst double blind controlled study on ris-
peridone in the treatment of preschool children with ASD 
(Jesner et al 2007). The aim of this research was to test the 
safety and effectiveness of this medication and to discover 
whether it could improve the core deﬁ  cits of ASD as well 
as interfere with behavioral symptoms. Children with PDD-
NOS not otherwise speciﬁ  ed and those undergoing behavioral 
treatment were included in the study in order to have a wider 
population of patients with ASD. Twenty four preschool chil-
dren aged 2.5–6 yrs who met DSM-IV diagnostic criteria for 
autism or PDD were recruited for participation. The principal 
outcome measurements were CARS and the Gillian autism 
rating scale that were administered at baseline, 2, 4, and 6 
months. Socialization and adaptive behavior were assessed 
at baseline and at the 6-month endpoint with the Vineland 
adaptive behavior scales. Risperidone was administered in 
low doses and the ﬁ  nal mean daily dose was 0.05 mg/kg. 
The duration of treatment was 6 months. Safety and efﬁ  cacy 
of treatment over the 6-month period was satisfactory. Side 
effects were relatively mild, as were weight gain, hypersali-
vation, and higher prolactin levels.
An overall amelioration, measured by means of the dif-
ference between CARS scores at baseline and at the end of 
treatment, was observed in this study in children receiving 
risperidone compared to those receiving placebo. However, 
it should be noted that many of the subjects of both groups 
were undergoing intensive behavioral treatment and different 
interpretations could be offered regarding the effect of this 
concomitant treatment. No speciﬁ  c improvements in autism 
domains were observed as a function of the treatment group, 
and this is in line with the ﬁ  ndings of the other double-blind Neuropsychiatric Disease and Treatment 2008:4(4) 728
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trials with risperidone in older children with ASD. This 
means that the core social and communication impairment of 
ASD were only mildly, if at all, affected by the treatment. The 
decrease in stereotypies, repetitive behaviors and hyperactiv-
ity obtained with risperidone therapy had a positive effect 
on the global functioning of children. A lack of objective 
measures other than symptoms expression and the lack of a 
more detailed assessment and structured clinical interview 
for ASD were the major limitations. Furthermore, the small 
number of subjects did not allow ﬁ  rm conclusions.
•  Nagaraj's study (Nagaraj et al 2006) [ages 6 yrs, risperi-
done dosage 1 mg/day as a ﬁ  xed dose, 63% improvement 
on CARS score].
A double-blind placebo controlled study in preschool 
children with ASD, aged 6 yrs, was conducted by Nagaraj 
and colleagues (2006) to test the efﬁ  cacy of risperidone in 
limiting irritability, aggressive behavior and hyperactivity 
and in improving the core symptoms of social and commu-
nication impairment (McDougle et al 2005). Forty children 
with a diagnosis of autism according to the DSM IV were 
enrolled for a 6 month trial with risperidone. The CARS, 
CGAS, and Global Impression of Parents were used and the 
mean changes from baseline to the end of 6 months period 
were the primary outcome measurements. A ﬁ  xed dose of 
1 mg/day was used to obtain more homogenous group data. 
Twelve of the 19 (63%) children in the risperidone group 
demonstrated an improvement of at least 20% in CARS 
however none of the children on placebo showed any favor-
able variations. On the CGAS, children in the risperidone 
group showed a score that was increased by at least 20%, 
and 94% were considered as improved to some extent or 
considerably improved according to the Global Impression 
of Parents rating. This study reported a positive outcome 
regarding the so-called target symptoms and an improvement 
in social and global functioning. It should be noted that only 
social responsiveness and nonverbal communication were 
considered to be improved, but no signiﬁ  cant variations 
were noted in language, speech or in stereotypies. Therefore 
core social and communication domains were still prominent 
affected areas of functioning. With regard to the unwanted 
effects, in this study mild and transient dyskinesia was seen 
in three children.
Discussion
The pharmacological approach in the use of risperidone 
for treating behavioral disturbances in children with ASD 
is on the increase, but the existing data are still limited and 
much caution is recommended when prescribing it in such a 
vulnerable population as that of children with ASD.
The four randomized control trials of risperidone have 
demonstrated the moderate and clinically signiﬁ  cant beneﬁ  ts 
in behavioral disturbances control, including disruptive 
behaviors, hyperactivity, stereotypies, and self-injury. The 
decreases in repetitive behaviors and self-injurious behavior 
(SIB) were particularly noteworthy since they are core symp-
toms of ASD. On the contrary, social and language impair-
ments were only slightly modiﬁ  ed by treatment, although 
results differed between studies. It is important to mention 
that patients selected for more severe behaviors at baseline, 
such as those that are probably enrolled in these studies, 
may show a greater treatment beneﬁ  t in target symptoms. 
Consequently, generalization of these ﬁ  ndings is not recom-
mended, and further investigations on broader clinical ASD 
populations are needed.
The multisite trial by the RUPPAN (2005) showed 
that repetitive movements and behaviors decreased with 
treatment, whereas social and language skills remained 
unchanged (McCracken et al 2002). Parents’ reports 
were in agreement with these ﬁ  ndings and supported the 
empirical data (Arnold et al 2003). However, the studies 
by Shea and colleagues (2004) and Nagaraj and colleagues 
(2006) also found the amelioration of some core aspects of 
communication and social withdrawal, but in the latter the 
outcome measurements and low numbers were insufﬁ  cient 
for drawing strong conclusions. Further research is needed 
to test this hypothesis and to replicate the above ﬁ  ndings in 
larger populations.
Risperidone doses varied from 0.01 mg/day to 0.05 
mg/day, and all the studies started with low doses and then 
increased them slowly. The initial dose was 0.25 to 0.5 
mg/day once or twice daily, with increments of 0.25 mg or 
0.5 every three to seven days until a therapeutic response 
was reached. Therefore, a ﬂ  exible schedule of dosing is 
advisable to coincide with characteristics of the child and to 
minimize unwanted side effects. Dosing guidelines have been 
provided in labeling for risperidone in many countries for 
children from 6–16 years of age, but they are not yet available 
for pre-school children. Therefore, careful monitoring and 
slow titration of medication are the mainstays of treatment, 
particularly in younger children.
Weight gain was the most frequent adverse event, ranging 
from 1 to 10 kg, at a of 2.7 kg in the Shea and colleagues 
(2004) and McCracken and colleagues (2002) studies and 
2.96 kg in preschoolers in the Luby and colleagues study 
(2006). Weight increase usually stabilizes over time, but it Neuropsychiatric Disease and Treatment 2008:4(4) 729
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is more pronounced during the ﬁ  rst 2–3 months of therapy. 
Several potential long term health risks arise with weight 
gain, such as hypertension, heart disease, diabetes, and dys-
lipidemia. Diet and physical activity should be suggested 
during the early phases of treatment with risperidone to limit 
weight gain. Sedation is another common side effect, but in 
most studies it is usually referred to as transient and it has 
not caused withdrawal or any other major effect.
An increase in prolactin levels is very common but 
monitoring is not required since the higher levels are predic-
tive of clinical symptoms. In the pooled data of the clinical 
trials the rise in mean values was observed during the ﬁ  rst 
two months of therapy (Findling et al 2003; Anderson et al 
2007). It is not yet possible to provide recommended levels 
of prolactin to be maintained during risperidone treatment 
due to the lack of data, but clinical monitoring of potentially 
related symptoms is recommended.
The occurrence of UEE was relatively low in these trials 
and it must be emphasized that they occur at high doses of 
risperidone. The maximum mean dose used was 2.08 mg/
day, in the low range, and this was probably a conservative 
approach which limited the occurrence of UEE. Once more, 
careful clinical monitoring is needed during risperidone 
treatment because the many common repetitive movements, 
including complex tics and sterotypies, in children with ASD 
may mask UEE.
There are still no guidelines for the duration of ris-
peridone treatment in children with ASD. The blinded 
discontinuation phase of the RUPPAN (2005) study after a 
6-month period of double blind risperidone treatment and 4 
months of open-label, demonstrated that a relapse in behav-
ioral symptoms was observed in a signiﬁ  cant percentage of 
children on placebo (10 out of 16), 2 months after stopping 
treatment, and yet this occurred in only 2 out of 16 patients 
on risperidone.
Several open trials on the use of risperidone in children 
and adolescents with ASD have been conducted (Table 2). 
They demonstrated similar overall ﬁ  ndings of those obtained 
by the controlled trials as to the effectiveness of risperidone 
on three major clinical domains of ASD. Limited effective-
ness of risperidone treatment was reported on core language 
and social impairment in most of them. In the Masi and 
colleagues (2003) study in preschoolers various degrees of 
improvement were observed in stereotypies and repetitive 
behaviors, affect modulation, SIB, and hyperactivity. In these 
open studies dosage and titration were similar to those used in 
controlled trials, indicating the general attitude of clinicians 
to proceed with low titration and to maintain low doses. The 
principal unwanted effects observed were increased appetite, 
weight gain and prolactin elevation, are reported in controlled 
trials (Table 1).
Empirical ﬁ  ndings suggest that risperidone should be 
maintained for a long period, eg, one or more years, using 
clinical parameters due to the lack of evidence-based guide-
lines. Treatment studies, including discontinuation studies, 
suggest is still warranted in ASD after 6 months, but routine 
periodic re-assessment of the need for continued treatment 
should be performed. Future investigation should address the 
important issues of long term follow-up and discontinuation 
of risperidone, since ASDs are long-lasting lifetime disorders. 
The main unwanted UEEs to be controlled in long term treat-
ment are tardive dyskinesia and akathisia.
Heterogeneity in study design and evaluation procedures 
among the different studies limited the critical analysis. 
Guidelines for pharmacological trials should be applied in 
future studies in order to obtain more comparable results 
regarding safety and efﬁ  cacy of treatment.
Finally the effects on the developing brain are unknown 
and concern is warranted. It is not known whether or how it 
could interfere with the maturational processes of the brain. 
The mechanisms of action that are effective in limiting 
behavioral disorders in ASD are likewise not yet known and 
should be investigated. Therefore there are several implica-
tions of early risperidone treatment on the neurobiology of 
development, and further research is needed to elucidate 
these aspects.
Conclusion
Moderate efﬁ  cacy and safety of risperidone for treating mal-
adaptive behaviors, including aggression, hyperactivity, self 
injury and irritability, have been documented in the available 
studies. Two studies also found some degree of improve-
ment in some of the core features of ASD. Risperidone was 
promising in preschoolers with ASD also combined with 
behavioral interventions. Further trials on larger popula-
tions and of longer duration are needed for obtaining more 
information on the tolerability and efﬁ  cacy of risperidone at 
a young age. Furthermore, the different biases, such as the 
tendency to enroll more severe cases in clinical trials, should 
be thoroughly controlled in future studies as subgroups of 
children that could be more responsive to treatment have 
been considered in current research. Efﬁ  cacy and tolerability 
of risperidone in the various types of PDDs, including the 
different degrees of severity of core symptoms, from mild 
to severe, are still undetermined and should be appropriately 
addressed. At present much caution is therefore warranted Neuropsychiatric Disease and Treatment 2008:4(4) 730
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in this vulnerable population that raises additional concerns 
and that needs continuous care, especially when receiving 
pharmacotherapy.
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